Ep. 801 - Recognizing Risk: Oral Potentially Malignant Disorders Explained

How confident are you that the white patch you noticed at your last exam wasn't something that needed a biopsy? The uncomfortable truth is that for every HPV-negative oral cancer, there was a visible precancerous lesion — and fewer than 5% of those lesions are identified before they become cancer.Dr. Ashley Clark is an Associate Professor and Division Chief of Oral Pathology at the University of Kentucky College of Dentistry. She holds a DDS from Indiana University and a certificate in Oral and Maxillofacial Pathology from the University of Florida. With over 40 published papers and abstracts, more than 200 continuing education courses delivered, a Fellowship in the American College of Dentists, a Fellowship in Health Education, and authorship of the oral pathology sections of both Dental Decks and Dental Hygiene Decks, Dr. Clark is one of the most prolific oral pathology educators in the country. She has earned multiple prestigious teaching awards, serves on the Commission on Dental Accreditation review board for oral and maxillofacial pathology programs, and sits on the Advisory Board for Oral Cancer Cause.In this episode, Dr. Clark breaks down the full spectrum of oral potentially malignant disorders (PMDs) — from leukoplakia and erythroplakia to erosive oral lichen planus and proliferative verrucous leukoplakia — and explains exactly why the dental profession is failing to intervene early enough. The conversation covers the clinical criteria that demand a biopsy with no exceptions, why the standard two-week watch-and-wait approach is inappropriate for sharply demarcated lesions, and how to structure long-term surveillance once a PMD is diagnosed. Dr. Clark also addresses the medicolegal exposure dentists face when PMDs go unmonitored, and makes a clear, evidence-based case that appropriately treating leukoplakia alone could reduce oral cancer rates by 50%.A sharply demarcated white lesion requires a biopsy regardless of patient history, smoking status, or lesion duration — no additional clinical information changes this decision. Watching such a lesion without a diagnosis is not a valid clinical strategy because it is impossible to treat something without knowing what it is, and the most common benign diagnosis is hyperkeratosis while the most common malignant result is squamous cell carcinoma.Autofluorescence devices can serve as a useful adjunct to white-light examination, but should not be used as standalone diagnostic tools. If a lesion loses fluorescence compared to surrounding healthy tissue, the clinician should return to white-light examination to determine whether the area is sharply demarcated — if it is, biopsy is indicated regardless of other findings.Once a PMD is diagnosed and treated, the standard of care supported by the literature requires monitoring every six months for 20 years, with each visit including photographic documentation and probe measurement of the lesion. Any change in size, surface character, or appearance at a surveillance visit warrants a new biopsy; if the lesion remains stable, continued observation without repeat biopsy is appropriate.When dysplasia is confirmed histologically, the recommended treatment escalates based on severity: mild dysplasia may be managed with laser ablation, while moderate dysplasia, severe dysplasia, or carcinoma in situ warrants surgical excision with a scalpel. After tissue destruction, the patient returns to the general dental office for long-term surveillance monitoring for recurrence or new sites of involvement.General dentists are technically capable of performing punch biopsies on accessible sites including attached gingiva, buccal mucosa, lateral tongue, dorsal tongue, labial mucosa, and hard palate. Sites including the floor of mouth, ventral tongue, soft palate, and gingival bumps with aesthetic considerations are better referred to oral surgery or periodontics; post-operative management of punch biopsy sites typically requires pressure hemostasis, chemical cauterization if needed, and a single suture for tongue sites, with minimal analgesic requirements for most patients.Perfect for: General dentists seeking clearer biopsy decision-making criteria, dental hygienists who perform oral cancer screenings, dental residents in any specialty, and practice owners who want to understand the medicolegal implications of PMD surveillance protocols.If you've ever hesitated before recommending a biopsy, this episode will give you the clinical framework and the conviction to act.